Signia Therapeutics is proud to welcome as new shareholders two experienced Biotech executives, Mr. Philippe Archinard CEO of Transgene and Mr. Fabrice Plasson CEO of Amoeba, as well as EZUS, a private subsidiary of the Université Claude Bernard Lyon. These investors will be part of Signia Therapeutics Strategic Committee bringing their strong expertise and networks to support the Company’s growth plans.
Laureate of the I-Lab 2017 award, Signia Therapeutics is an emerging company, spin-off company of VirPath laboratory/Université Claude Bernard Lyon (UCBL), that proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses.
Focus on Signia Therapeutics, a breakthrough strategy against respiratory viruses.
Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery and repositioning. Signia Therapeutic’s drug discovery platform has demonstrated its significant potential with proofs-of-concept already established for several FDA-approved drugs that were validated for new anti-influenza and anti-MERS-CoV indications. Ongoing programs are currently conducted and dedicated to the selection and validation of new broad-spectrum antiviral compounds against human respiratory syncytial virus, human metapneumovirus and human coronaviruses.
From the left to the right : Dr Guy Boivin (Canada Research Chair on Influenza Viruses and Other Respiratory Viruses), Dr Olivier Terrier (Researcher CNRS VirPath), Michel Cousineau (CEO of Signia Therapeutics), Dr Manuel Rosa-Calatrava (Research Director INSERM and Deputy Director of VirPath) et Dr Andrés Pizzorno (Researcher, VirPath).
Research programs whose results led to the creation of Signia Therapeutics, were conducted jointly with Dr Guy Boivin’ team at Québec (Université Laval/CRI/CHU Québec) with the support of funding from the National Research Agency, INSERM, Université Claude Bernard Lyon, Université of Laval and the Auvergne Rhône-Alpes Region.
Very proud to announce that Signia Therapeutics is laureate of the i-lab 2017 award from the French Ministry of Higher Education, Research and Innovation, and BpiFrance.
Many thanks to the Université Claude Bernard Lyon 1, its subsidiaries Lyon Ingénierie Projets and EZUS Lyon 1, the Région Auvergne Rhône-Alpes and DGOS/INSERM for their strong supports on our research programs.
Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1, that proposes a breakthrough strategy for the repurposing of marketed drugs as new broad Spectrum antiviral compounds. Signia Therapeutics develops an innovative and versatile platform for antiviral drug discovery and repurposing based on globally targeting the host cell instead of specific viral molecular determinants. This novel proprietary development strategy has already a proven track record and is based on a solid set of proofs of concept.
The Company’s strategy is well adapted to the pathogenesis of respiratory acute infections and provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative strategy and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development.
Pr. Frédérique Vidal, Secretary of French Ministry of Higher Education, Research and Innovation, congratulated the i-lab 2017 laureates and also reminded that the innovation was the key of the growth, the competitiveness and the employment.
The Foreign Post-doctoral Researcher 2017 « Grand Prix » of the « les Amis de l’Université de Lyon » association (AAUL) was awarded to Dr. Andrés Pizzorno for his work on respiratory viruses and his contribution to the development of novel antiviral drugs.
The AAUL jury has particularly congratulated Dr Andrés Pizzorno for his valorization and technologic transfer activities within VirPath laboratory. The AAUL is an association founded in 1889 which promotes the diversity and excellence of education and research programs driven by the University of Lyon. This AAUL award highlights a foreign post-doctoral researcher who has completed at least six months within a laboratory of the University of Lyon working on global health and society or sustainable development.
Press release : « VirPath et VetAgro Sup, un partenariat de recherche en santé humaine et animale combiné à une offre académique de recherche unique en France »
Since April 2016, VirPath laboratory (CIRI-INSERM/CNRS/ENS/UCBL) and Institut Claude Bourgelat (VetAgro Sup) have worked together and set up ferret model of influenza infections in order to evaluate new vaccine candidates.